ATE284701T1 - Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren - Google Patents

Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren

Info

Publication number
ATE284701T1
ATE284701T1 AT01913267T AT01913267T ATE284701T1 AT E284701 T1 ATE284701 T1 AT E284701T1 AT 01913267 T AT01913267 T AT 01913267T AT 01913267 T AT01913267 T AT 01913267T AT E284701 T1 ATE284701 T1 AT E284701T1
Authority
AT
Austria
Prior art keywords
vegf
cells
tumor
screening
methods
Prior art date
Application number
AT01913267T
Other languages
English (en)
Inventor
Marc Ludwig Achen
Steven Ludwig Stacker
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE284701T1 publication Critical patent/ATE284701T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01913267T 2000-03-02 2001-03-02 Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren ATE284701T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18636100P 2000-03-02 2000-03-02
PCT/US2001/006791 WO2001064235A1 (en) 2000-03-02 2001-03-02 Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d

Publications (1)

Publication Number Publication Date
ATE284701T1 true ATE284701T1 (de) 2005-01-15

Family

ID=22684635

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01913267T ATE284701T1 (de) 2000-03-02 2001-03-02 Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren
AT04027975T ATE533056T1 (de) 2000-03-02 2001-03-02 Verfahren zum auffinden von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04027975T ATE533056T1 (de) 2000-03-02 2001-03-02 Verfahren zum auffinden von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren

Country Status (12)

Country Link
US (1) US20010038842A1 (de)
EP (1) EP1259248B1 (de)
JP (1) JP2003525248A (de)
KR (1) KR20020080461A (de)
AT (2) ATE284701T1 (de)
AU (1) AU4194601A (de)
CA (1) CA2401665A1 (de)
DE (1) DE60107815T2 (de)
ES (2) ES2234818T3 (de)
NZ (1) NZ520546A (de)
PT (1) PT1259248E (de)
WO (1) WO2001064235A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
EP2298311B1 (de) 1999-01-13 2012-05-09 Bayer HealthCare LLC Omega-carboxyarylsubstituierte-Diphenyl-Harnstoffe als p38-Kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
JP4669984B2 (ja) * 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
AU2002322461B2 (en) * 2001-07-12 2007-12-06 Vegenics Limited Lymphatic endothelial cells materials and methods
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7666979B2 (en) 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
AU2004209668A1 (en) * 2003-02-04 2004-08-19 Flanders Interuniversity Institute For Biotechnology VEGF-B and PDGF modulation of stem cells
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
ES2557286T3 (es) 2003-03-03 2016-01-25 Dyax Corp. Usos de péptidos que se unen específicamente al receptor del HGF (cMet)
RU2248183C2 (ru) * 2003-03-11 2005-03-20 НИИ онкологии им. проф. Н.Н. Петрова Минздрава РФ Способ интраоперационной диагностики степени распространенности опухолевого процесса при колоректальном раке
EP1636585B2 (de) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl-harnstoffe mit kinasehemmender wirkung
WO2005011722A2 (en) * 2003-06-12 2005-02-10 Ludwig Institute For Cancer Research Use of vegf-c or vegf-d in reconstructive surgery
US20050032697A1 (en) * 2003-06-12 2005-02-10 Kari Alitalo Heparin binding VEGFR-3 ligands
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
US20050239700A1 (en) * 2003-10-14 2005-10-27 Biogen Idec Inc. Treatment of cancer using antibodies to LRRC15
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
WO2011156451A2 (en) * 2010-06-08 2011-12-15 The Cleveland Clinic Foundation Compositions and methods for modulating toll-like receptor 2 activation
US9981018B2 (en) 2010-06-08 2018-05-29 The Cleveland Clinic Foundation Compositions and methods for modulating toll-like receptor 2 activation
MY170528A (en) 2013-02-18 2019-08-09 Vegenics Pty Ltd Vegfr-3 ligand binding molecules and uses thereof
CN103739710B (zh) * 2014-01-26 2015-12-09 中国人民解放军军事医学科学院基础医学研究所 一种抗vegf抗体及其应用
US20200062836A1 (en) * 2016-11-16 2020-02-27 Eli Lilly And Company THERAPY FOR METATASTIC COLORECTAL CANCER USING ANTI-VEGFR-2 and ANTI-VEGF-D ANTIBODIES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69733204T3 (de) * 1996-07-15 2012-03-08 Chugai Seiyaku K.K. Neuartige vegf-ähnliche faktoren
EP0956339B1 (de) * 1996-08-23 2005-10-12 Ludwig Institute For Cancer Research Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)
CA2315977A1 (en) * 1997-12-24 1999-07-08 Ludwig Institute For Cancer Research Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas
PT1140175E (pt) * 1998-12-21 2006-06-30 Ludwig Inst Cancer Res Anticorpos para o vegf-d truncado e suas utilizacoes
CZ20014444A3 (cs) * 1999-06-11 2002-05-15 Aventis Pharmaceuticals Products Inc. Protein Akt pro pouľití k indukci exprese VEGF

Also Published As

Publication number Publication date
EP1259248B1 (de) 2004-12-15
US20010038842A1 (en) 2001-11-08
ES2377119T3 (es) 2012-03-22
ES2234818T3 (es) 2005-07-01
CA2401665A1 (en) 2001-09-07
JP2003525248A (ja) 2003-08-26
KR20020080461A (ko) 2002-10-23
AU4194601A (en) 2001-09-12
EP1259248A1 (de) 2002-11-27
EP1259248A4 (de) 2003-05-28
ATE533056T1 (de) 2011-11-15
NZ520546A (en) 2004-05-28
DE60107815T2 (de) 2005-12-08
WO2001064235A1 (en) 2001-09-07
PT1259248E (pt) 2005-04-29
DE60107815D1 (de) 2005-01-20

Similar Documents

Publication Publication Date Title
DE60107815D1 (de) Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren
Whyte et al. Wnt signaling and injury repair
Sierra et al. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages
van den Broek et al. Suppressed inflammatory gene expression during human hypertrophic scar compared to normotrophic scar formation
Garcia-Areas et al. Semaphorin7A promotes tumor growth and exerts a pro-angiogenic effect in macrophages of mammary tumor-bearing mice
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
AU2003253986A8 (en) Gene expression profiling in biopsied tumor tissues
DE60126592D1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
WO2005065418A3 (en) Compositions and methods of use of targeting peptides for diagnosis and therapy
WO2005034843A3 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
Ahuja et al. Multifaceted TGF‐β signaling, a master regulator: From bench‐to‐bedside, intricacies, and complexities
Konop et al. Keratin-Butyrate scaffolds promote skin wound healing in diabetic rats through Down-Regulation of IL-1β and Up-Regulation of keratins 16 and 17
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
Timmons et al. Injection of syngeneic murine melanoma cells to determine their metastatic potential in the lungs
Boueuf et al. Inhibition of adhesion breast cancer cells by anticoagulant drugs and cimetidine
Rubens The nature of metastatic bone disease
ATE366936T1 (de) Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
ATE382347T1 (de) Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
Arjama Establishment of patient-derived cancer models from melanoma for functional drug sensitivity and resistance testing
Ho et al. Breast nodularity and ulceration: diffuse dermal angiomatosis a corticosteroid responsive disease
WO2003076651A3 (en) Cancer associated araf1 protein kinase and its uses
Badžek et al. Treatment of cancer-related anemia
Wronski et al. 1273 Crispr/cas9 mediated knockout of ripk4 impairs spheroid formation and wnt/β-catenin signaling in melanoma cells
Casalou et al. 1272 p21Waf1/Cip1 is differentially expressed in epidermal versus follicular melanocytes and melanoma cells and is phenotypically regulated by UVB-mediated apoptosis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1259248

Country of ref document: EP

REN Ceased due to non-payment of the annual fee